NasdaqGS:PHVSPharmaceuticals
Did FDA’s NDA Acceptance for Deucrictibant Just Shift Pharvaris' (PHVS) Hereditary Angioedema Narrative?
Earlier this month, Pharvaris announced that the FDA accepted its New Drug Application for deucrictibant immediate-release 20 mg capsules for on-demand treatment of Hereditary Angioedema attacks, supported by Phase 3 RAPIDe-3 data covering more than 1,300 treated attacks.
The filing showcases an oral bradykinin B2 receptor antagonist that achieved rapid symptom relief, End of Progression, and complete attack resolution with statistical significance across all primary and secondary endpoints...